IONS Institutional Ownership

IONIS PHARMACEUTICALS INC

Latest close $54.19 as of Aug 5, 2026

Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices. Form 13F rows are quarter-end holding context only and do not establish an exact entry date.

Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes. Filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro. The overall institutional consensus preview remains public. Compare plans.

Cross-institution intelligence

Institutional Research

Each institution is compared with its own prior filing, then the latest institution-level directions are compared for breadth.

Latest filing May 15, 2026

Public consensus preview Reduction leaning 34/100 institutional research score

2 tracked institutions Latest filing May 15, 2026

1 reducing across 1 comparable institution.

Accumulating0

Unchanged0

Reducing1

Exited0

The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.

Price context

52-week position is market context and does not change the institutional consensus score.

52-week low$23.95 52-week high$86.74

Latest close $54.19 48.2% through the range

Tracked institutions

Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.

Latest observation Mar 31, 2026

BlackRock Legacy Jan 26, 2024 filed

T. Rowe Price Investment Management May 15, 2026 filed

Detailed institutional research

See what is driving the consensus.

Unlock holder-by-holder changes, ownership history, breadth by period, disclosure timing, and filing-specific signal analysis.

Create free account Compare Investor and Pro

A free account adds watchlists and reveals tracker research gauges. Investor or Pro unlocks the detailed research above.

Beneficial ownership filing history

Showing 3 of 6 parsed filing(s) · 3 older require more history access

Holder	Observed / filed	Reported change	Shares	Ownership	Observation	Filing	Latest
T. Rowe Price Investment Management CIK0001897612	Mar 31, 2026 observed May 15, 2026 filed · 45d Schedule 13G amendment	Reported reduction	6.2M -2.9M	12.00% 0.00 pts	$75.09	$74.23	$54.19
T. Rowe Price Investment Management CIK0001897612	Dec 31, 2025 observed Feb 17, 2026 filed · 48d Schedule 13G amendment	Reported reduction	9.1M -4.0M	12.00% 0.00 pts	$79.11	$81.36	$54.19
T. Rowe Price Investment Management CIK0001897612	Sep 30, 2025 observed Nov 14, 2025 filed · 45d Schedule 13G amendment	Reported reduction	13.2M -2.7M	12.00% 0.00 pts	$65.42	$71.55	$54.19

Explore more institutional activity

Related research

Crawlable links to other securities with similar institutional consensus or recent multi-institution accumulation.

Similar research strength

SAMG SILVERCREST ASSET MANAGEME-A 34/100 Reduction leaning SBYSF SIBANYE STILLWATER LTD 34/100 Reduction leaning OTEX OPEN TEXT CORP 34/100 Reduction leaning ODD ODDITY TECH LTD-CL A 34/100 Reduction leaning

Recent multi-institution accumulation

TVTX TRAVERE THERAPEUTICS INC 2 accumulating Aug 6, 2026 PCVX VAXCYTE INC 2 accumulating Aug 6, 2026 VVX V2X INC 2 accumulating Aug 6, 2026 VSEC VSE CORP 3 accumulating Jul 31, 2026